Latest Insider Transactions at Bei Gene, Ltd. (BGNE)
This section provides a real-time view of insider transactions for Bei Gene, Ltd. (BGNE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BeiGene, Ltd. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BeiGene, Ltd.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 14
2024
|
John Oyler Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,300,000
+30.38%
|
$0
$0.5 P/Share
|
|
Dec 10
2024
|
Xiaodong Wang Director |
SELL
Open market or private sale
|
Direct |
41,760
-41.7%
|
$7,892,640
$189.29 P/Share
|
|
Dec 10
2024
|
Xiaodong Wang Director |
BUY
Exercise of conversion of derivative security
|
Direct |
41,760
+50.0%
|
$250,560
$6.5 P/Share
|
|
Dec 09
2024
|
Baker Bros. Advisors LP |
SELL
Open market or private sale
|
Indirect |
1,037,017
-4.92%
|
$204,292,349
$197.25 P/Share
|
|
Dec 06
2024
|
Xiaobin Wu President, COO & GM China |
SELL
Open market or private sale
|
Indirect |
0
|
-
|
|
Dec 02
2024
|
Hhlr Advisors, Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
17,842,500
-12.49%
|
$3,568,500,000
$200.0 P/Share
|
|
Nov 26
2024
|
Xiaodong Wang Director |
SELL
Open market or private sale
|
Indirect |
7,883
-40.87%
|
$1,489,887
$189.62 P/Share
|
|
Nov 26
2024
|
Xiaodong Wang Director |
SELL
Open market or private sale
|
Direct |
40,468
-21.29%
|
$7,648,452
$189.69 P/Share
|
|
Nov 26
2024
|
Xiaodong Wang Director |
BUY
Exercise of conversion of derivative security
|
Direct |
38,461
+48.73%
|
$230,766
$6.5 P/Share
|
|
Oct 08
2024
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
10,000
-35.4%
|
$2,320,000
$232.77 P/Share
|
|
Oct 08
2024
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
6,175
-35.41%
|
$1,432,600
$232.77 P/Share
|
|
Sep 30
2024
|
Shalini Sharp Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,151
+50.0%
|
-
|
|
Sep 30
2024
|
Chan Henry Lee SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
1,202
-100.0%
|
$284,874
$237.1 P/Share
|
|
Sep 27
2024
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Indirect |
5,000
-100.0%
|
$1,100,000
$220.35 P/Share
|
|
Sep 19
2024
|
Xiaobin Wu President, COO & GM China |
SELL
Open market or private sale
|
Direct |
4,500
-100.0%
|
$900,000
$200.14 P/Share
|
|
Sep 17
2024
|
Xiaobin Wu President, COO & GM China |
SELL
Open market or private sale
|
Direct |
500
-10.0%
|
$100,000
$200.0 P/Share
|
|
Sep 03
2024
|
Titus B. Ball Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
137
-100.0%
|
$25,893
$189.94 P/Share
|
|
Sep 03
2024
|
Xiaobin Wu President, COO & GM China |
SELL
Open market or private sale
|
Direct |
5,556
-57.25%
|
$1,055,640
$190.13 P/Share
|
|
Aug 12
2024
|
Xiaodong Wang Director |
SELL
Bona fide gift
|
Direct |
301,457
-5.41%
|
-
|
|
Aug 09
2024
|
Aaron Rosenberg Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
118,547
+50.0%
|
-
|
|
Jul 30
2024
|
Chan Henry Lee SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
834
-100.0%
|
$133,440
$160.57 P/Share
|
|
Jul 01
2024
|
Julia Aijun Wang Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
472
-100.0%
|
$67,496
$143.9 P/Share
|
|
Jun 24
2024
|
Xiaobin Wu President, COO & GM China |
SELL
Open market or private sale
|
Direct |
1,459
-88.52%
|
$233,440
$160.39 P/Share
|
|
Jun 24
2024
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Direct |
1,064
-99.91%
|
$170,240
$160.45 P/Share
|
|
Jun 24
2024
|
Julia Aijun Wang Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
899
-100.0%
|
$139,345
$155.66 P/Share
|
|
Jun 24
2024
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,789
-92.83%
|
$443,451
$159.81 P/Share
|
|
Jun 18
2024
|
Xiaobin Wu President, COO & GM China |
SELL
Open market or private sale
|
Direct |
2,627
-63.21%
|
$404,558
$154.95 P/Share
|
|
Jun 18
2024
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Direct |
841
-100.0%
|
$128,673
$153.75 P/Share
|
|
Jun 17
2024
|
Xiaobin Wu President, COO & GM China |
SELL
Open market or private sale
|
Direct |
627
-19.27%
|
$99,693
$159.0 P/Share
|
|
Jun 17
2024
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Direct |
1,500
-22.24%
|
$238,500
$159.2 P/Share
|
|
Jun 17
2024
|
Julia Aijun Wang Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
916
-46.76%
|
$144,728
$158.89 P/Share
|
|
Jun 17
2024
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,281
-61.66%
|
$203,679
$159.28 P/Share
|
|
Jun 17
2024
|
Chan Henry Lee SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
439
-61.65%
|
$69,801
$159.21 P/Share
|
|
Jun 05
2024
|
Xiaobin Wu President, COO & GM China |
BUY
Grant, award, or other acquisition
|
Direct |
253,409
+16.65%
|
-
|
|
Jun 05
2024
|
Titus B. Ball Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,427
+33.77%
|
-
|
|
Jun 05
2024
|
Anthony C Hooper Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,341
+23.31%
|
-
|
|
Jun 05
2024
|
Olivier Brandicourt Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,341
+50.0%
|
-
|
|
Jun 05
2024
|
Margaret Dugan Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,341
+26.23%
|
-
|
|
Jun 05
2024
|
Chan Henry Lee SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
98,085
+26.69%
|
-
|
|
Jun 05
2024
|
Lai Wang Global Head of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
168,935
+8.72%
|
-
|
|
Jun 05
2024
|
Corazon (Corsee) D. Sanders Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,341
+26.11%
|
-
|
|
Jun 05
2024
|
Xiaodong Wang Director |
BUY
Grant, award, or other acquisition
|
Direct |
108,992
+1.92%
|
-
|
|
Jun 05
2024
|
Alessandro Riva Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,341
+26.23%
|
-
|
|
Jun 05
2024
|
Donald W. Glazer Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,341
+0.6%
|
-
|
|
Jun 05
2024
|
John Oyler Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
490,464
+21.3%
|
-
|
|
Jun 05
2024
|
Julia Aijun Wang Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
136,240
+22.99%
|
-
|
|
Jun 05
2024
|
Qingqing Yi Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,341
+26.23%
|
-
|
|
Jun 05
2024
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
65,364
+20.58%
|
-
|
|
Apr 11
2024
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
12,084
-67.24%
|
$1,764,264
$146.88 P/Share
|
|
Apr 10
2024
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
26,716
-23.46%
|
$3,980,684
$149.55 P/Share
|